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Abstract
Background: Breast cancer is a heterogeneous disease in terms of transcriptional aberrations; moreover, microarray
gene expression profiles had defined 5 molecular subtypes based on certain intrinsic genes. This study aimed to
evaluate the prediction consistency of breast cancer molecular subtypes from 3 distinct intrinsic gene sets (Sørlie
500, Hu 306 and PAM50) as well as clinical presentations of each molecualr subtype in Han Chinese population.
Methods: In all, 169 breast cancer samples (44 from Taiwan and 125 from China) of Han Chinese population were
gathered, and the gene expression features corresponding to 3 distinct intrinsic gene sets (Sørlie 500, Hu 306 and
PAM50) were retrieved for molecular subtype prediction.
Results: For Sørlie 500 and Hu 306 intrinsic gene set, mean-centring of genes and distance-weighted
discrimination (DWD) remarkably reduced the number of unclassified cases. Regarding pairwise agreement, the
highest predictive consistency was found between Hu 306 and PAM50. In all, 150 and 126 samples were assigned
into identical subtypes by both Hu 306 and PAM50 genes, under mean-centring and DWD. Luminal B tended to
show a higher nuclear grade and have more HER2 over-expression status than luminal A did. No basal-like breast
tumours were ER positive, and most HER2-enriched breast tumours showed HER2 over-expression, whereas, only
two-thirds of ER negativity/HER2 over-expression tumros were predicted as HER2-enriched molecular subtype. For
44 Taiwanese breast cancers with survival data, a better prognosis of luminal A than luminal B subtype in ER-
postive breast cancers and a better prognosis of basal-like than HER2-enriched subtype in ER-negative breast
cancers was observed.
Conclusions: We suggest that the intrinsic signature Hu 306 or PAM50 be used for breast cancers in the Han
Chinese population during molecular subtyping. For the prognostic value and decision making based on intrinsic
subtypes, further prospective study with longer survival data is needed.
Background
In the past decade, microarray experiments have redefined
breast cancers as heterogeneous diseases in terms of tran-
scriptional aberrations, and a number of taxonomic classi-
fications based on gene-expression profiles that have been
reported have shown some prognostic significance. One
such molecular taxonomy is the ‘intrinsic subtype’ pro-
posed by the Stanford group. Perou identified 476 intrinsic
genes from 65 patients with breast cancers and normal
individuals; four subclasses: basal-like, Erb-B2+, normal
breast-like, and luminal epithelial/ER+ were revealed by
class discovery through clustering analysis [1,2]. The lumi-
nal subtype was further divided into luminal A and B, and
distant metastases were strongly associated with the
expression patterns of intrinsic genes [3]. Independent stu-
dies supporting the existence of breast cancer intrinsic
* Correspondence: chuangey@ntu.edu.tw
1Graduate Institute of Biomedical Electronics and Bioinformatics, National
Taiwan University, Taipei City, Taiwan
Full list of author information is available at the end of the article
Huang et al. Journal of Translational Medicine 2012, 10(Suppl 1):S10
http://www.translational-medicine.com/content/10/S1/S10
© 2012 Huang et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
subtypes followed [4,5]. By definition, intrinsic genes were
those genes that show the highest variation across differ-
ent subjects and show the least variation within each indi-
vidual (i.e. pre-/post-chemotherapy changes) [3]. The
latest version of intrinsic signatures, prediction analysis of
microarray 50 gene set (PAM50), was supposed to provide
prognostic and predictive values independent of traditional
prognostic factors such as hormone receptor, human epi-
dermal growth factor receptor 2 (HER2) over-expression,
or proliferation markers [6].
Although much attention has been drawn and intense
arguments have been made, serious concerns about the
true existence and reproducibility of intrinsic signatures
remain. For instance, Lusa debated the comparability of
study populations and concluded that assigning of new
samples, which were not a part of the original dataset
from which the intrinsic genes were derived to molecular
subtypes was elusive [7]. Recently, Weigelt compared the
agreement in subtype assignment across 3 different
intrinsic genes-based single sample predictor (SSP) and
found only fair to substantial pairwise agreement [8].
Indeed, the degree of overlap between distinct intrinsic
gene lists was surprisingly low, although most of these
molecular signatures were claimed to have some prog-
nostic values [9]. The reproducibility and robustness of
molecular subtypes from intrinsic genes by hierarchical
clustering was also challenged [7,10].
In the current study, we evaluated the application of
molecular subtypes across ethnic groups. Predictive con-
sistency across different intrinsic gene sets as well as the
impact of systemic microarray bias adjustment was
assessed for Taiwanese and Chinese breast cancer patients,
both of Han Chinese origin. Clinical and pathological fea-
tures of each molecular subtype were compared
accordingly.
Methods
Study population and microarray experiments
The study material included 169 breast cancers of Han
Chinese population; 44 were from Taiwan, and 125, from
Mainland China. Regarding the Taiwanese samples, spora-
dic breast cancer samples were collected consecutively
during surgery, snapped frozen in liquid nitrogen, and
then stored and transported at -800C from January 2007
to January 2008. The frozen samples were dissected into
slices of 1-2 mm thickness, and more than 90% of the can-
cerous content was a pre-requisite for microarray experi-
ments. All examinations and management of the surgical
specimens were carried out by 2 qualified pathologists
(YYW and CYL). Written consent was obtained for all
subjects before sample collection, and the study protocol
was approved by Institute Review Board of Cathay General
Hospital. The criteria of enrolment included incident/inva-
sive breast cancers without neo-adjuvant therapy, no
systemic spread (clinical stage I to III), no concurrent sec-
ondary malignancy, and less than 70 years of age.
Total RNA was extracted by TRIzol® reagent (Invitro-
gen, Carlsbad, CA) and the RNA was purified using
RNeasy® mini kits (Qiagen, Germantown, MD). RNA inte-
gration was tested by gel electrophoresis. Affymetrix®
(Affymetrix, Santa Clara, CA) GeneChip® Human Gen-
ome U133 plus 2.0 was used for the microarray experi-
ment. Hybridization and scanning were performed
according to a standard protocol. Images were scanned
using GeneChip® Scanner 3000, and the scanned images
were processed with GeneChip® Operating Software
(GCOS). Robust multi-array average (RMA) algorithm was
used to normalize 44 array chips [11]. For the 125 samples
from China, raw expression files (CEL files) were down-
loaded from NCBI Gene Expression Omnibus (GSE5460)
by using the same Affymetrix® U133 plus 2.0 arrays and
normalized by RMA; details of the study are described
elsewhere and the study was approved by local IRB [12].
The processed expression profiles of breast cancers from
Taiwan and Mainland China were pooled together, and
quantile normalization was performed to remove the
batch effect between the breast cancer in Taiwanese
patients and Chinese patients.
For relevant pathological features, estrogen receptor
(ER) positivity was defined as the presence of at least 10%
of nuclei with positive results of immunohistochemical
(IHC) analysis, and breast samples displaying low ER posi-
tivity (1-9% of nuclei with positive stains) were not assayed
in current study. For HER2 status, the ASCO and CAP
guidelines were followed; IHC 3+ and IHC 2+ with fluor-
escence in-situ (FISH) hybridization amplification were
considered to indicate HER2 over-expression. The modi-
fied Bloom-Richardson (Nottingham) system was used for
grading breast cancers. The demographic features of the
169 Han Chinese patients with breast cancers are sum-
marized in Table 1.
Intrinsic gene lists and prototypical samples
Three intrinsic signatures that defined 5 molecular sub-
types (luminal A, luminal B, normal breast-like, HER2-
enriched, and basal-like) were Sørlie 500, Hu 306 and
PAM50 [3,4,6]. These different sets of intrinsic genes pre-
sented a chronological evolution of molecular subtypes
proposed by the Stanford group. The expression values of
training samples deriving intrinsic signatures were down-
loaded from Stanford Genomics Breast Cancer Consor-
tium and UNC Microarray Database (see Additional file 1
for details). Centroids were the mean expression values of
intrinsic genes corresponding to each molecular subtype.
Single sample prediction and systemic bias adjustment
All intrinsic genes were mapped to the Affymetrix gene
annotation file, and the data of the genes represented by
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multiple-probesets were averaged (see Additional file 1
for details of mapping process). The 169 breast cancer
specimens of the Han Chinese patients were assigned to
1 of the 5 molecular subtypes with the nearest centroid
(single sample prediction). Spearman’s rank correlation
coefficients were used, and samples were designated as
unclassified if correlation coefficients to all 5 centroids
were less than 0.1.
To enhance the comparability between the original
studies deriving intrinsic genes and independent samples
in current study, we applied 2 systemic bias-adjustment
methods, mean-centring of genes and distance-weighted
discrimination (DWD), to the expression data of Han
Chinese breast cancers, as suggested by the investigators
of the Stanford group [13,14].
Results
Distributions of molecular subtypes
Table 2 shows the distribution of molecular subtypes
under different combinations of intrinsic genes and
adjustment methods. Without adjustment, both Sørlie
500 and Hu 306 identified many unclassified samples,
and the number of unclassified samples reduced rapidly
when gene centring or DWD was applied, indicating the
necessity of bias adjustment across microarray studies.
The shift between the 2 luminal subtypes A and B was
prominent with and without adjustment; however, the
direction of this shift was unpredictable from the cur-
rent study. On the other hand, PAM50 was less sensitive
to systemic microarray bias correction. Regardless of the
adjustment, the least changes were observed for the
basal-like subtype across all 3 intrinsic genes. We also
noticed that PAM50 identified many normal breast-like
tumours under DWD.
Agreement between adjustment methods with the same
intrinsic genes
For Sørlie 500 and Hu 306, mean-centring of genes and
DWD showed good agreement in subtype assignment
(unweighted kappa: 0.83 and 0.95, respectively). For
PAM50, gene centring and original data showed the
highest predictive consistency (unweighted kappa: 0.80),
followed by gene centring and DWD, then original data
and DWD (unweighted kappa: 0.67 and 0.66, respec-
tively, Table 3).
Agreement between intrinsic gene sets with the same
adjustment
Table 3 also shows pairwise agreement between the 3
intrinsic gene sets. When genes were mean-centred,
Hu306 and PAM50 showed the highest agreement
(unweighted kappa: 0.85), and the consistency dropped
substantially (unweighted kappa: 0.67) when DWD was
adopted for adjustment. Sørlie 500 intrinsic genes
Table 1 Demographic features of study population
Source Taiwan China Total
n=44 n=125 n=169
ER
Positive 22(50%) 74(59%) 96(57%)
Negative 22(50%) 51(41%) 73(43%)
HER2
Over-expressed 21(48%) 30(24%) 51(30%)
Not 23(52%) 95(76%) 118(70%)
Nuclear grade
I 3(7%) 27(22%) 30(18%)
II 18(41%) 31(25%) 49(29%)
III 23(52%) 67(54%) 90(53%)
Nodal status
Positive 23(52%) 61(49%) 84(50%)
Negative 21(48%) 64(51%) 85(50%)
Lympovascular invasion*
Positive 27(63%) 46(37%) 73(43%)
Negative 16(37%) 79(63%) 95(57%)
*one missing value
Table 2 Molecular subtype distrubutions of 169 Han
Chinese breast cancers with different intrinsic genes and
adjustment
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showed only substantial agreement with Hu 306 and
PAM50 under gene centring or DWD (see Additional
file 2 for supplementary Table S2).
Clinical features of molecular subtypes
The breast cancer samples assigned to identical subtypes
with both Hu 306 and PAM50 intrinsic genes were
retrieved. These included samples from 150 (89%) and
126 (75%) of the 169 study subjects under gene centring
and DWD adjustment, respectively. In the most strin-
gent conditions, 117 (69%) samples were consistently
assigned to identical subtypes under both DWD and
gene centring. Their clinical features are presented in
Table 4 (supplementary Table S1 for molecular subtypes
stratified by clinical phenotypes); luminal B tended to
show a higher nucler grade and HER2 over-expression
than luminal A did. No basal-like breast tumours were
ER positive, and most HER2-enriched breast tumours
showed HER2 over-expression and were clinically ER
negative, whereas, only two-thirds of tumours that
showed ER negativity/HER2 over-expression were pre-
dicted as HER2-enriched molecular subtype.
For 44 Taiwanese breast cancers, clinical follow-up
was available up to 62 months (median:44.5). There
were 10 events of distant metastasis or mortality attribu-
ted to breast cancers. Figure 1(a) showed that there was
no significant event-free survival difference among the 5
molecular subtypes (log-rank test: 0.13, with Hu 306
intrinsic genes and gene-centring adjustment), better
prognosis of luminal A and compromised survival of
Table 3 Agreement between intrinsic gene sets and adjustment methods
Intrinsic genes Kappa* 95% CI Adjustment method Kappa* 95% CI
Sørlie 500 Gene centring
Original data vs. gene centring 0.51 0.43-0.60 Sørlie 500 vs. Hu 306 0.58 0.50-0.67
Original data vs. DWD 0.49 0.41-0.57 Sørlie 500 vs. PAM50 0.52 0.43-0.61
Gene centring vs. DWD 0.83 0.77-0.90 Hu306 vs. PAM50 0.85 0.79-0.91
Hu 306 DWD adjusted
Original data vs. gene centring 0.51 0.43-0.58 Sørlie 500 vs. Hu 306 0.56 0.47-0.65
Original data vs. DWD 0.5 0.42-0.58 Sørlie 500 vs. PAM50 0.55 0.47-0.64
Gene centring vs. DWD 0.95 0.92-0.99 Hu306 vs. PAM50 0.67 0.59-0.76
PAM50
Original data vs. gene centring 0.8 0.73-0.87
Original data vs. DWD 0.66 0.58-0.75
Gene centring vs. DWD 0.67 0.58-0.75
Table 4 Clinical features of agreeing samples between Hu 306 and PAM50 (n=117 with both mean-centring and DWD
adjustment)
Clinical factor Molecular subtype
Luminal A Luminal B Normal-breast like Basal-like HER2-enriched
ER
Positive 35 15 2 0 3
Negative 0 1 4 39 18
HER2
over-expressed 2 5 2 2 18
not over-expressed 33 11 4 37 3
Nuclear grade
I 17 0 1 0 0
II 16 4 2 2 4
III 2 12 3 37 17
Nodal status
Positive 16 9 5 10 14
Negative 19 7 1 29 7
Lymphovascular invasion*
Positive 14 11 4 11 13
Negative 21 5 2 28 8
*One missing value
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luminal B and HER2-enriched subtype was apparent
though. For ER-positive patients, luminal A outper-
formed luminal B while in ER-negative cancers, the
prognosis of basal-like subtype was better than HER2-
enriched subtype for Taiwanese breast cancers (Figure 1
(b) and 1(c), respectively).
Discussion
In the current study, we evaluated the trans-ethnic
applicability of breast cancer molecular subtypes for
independent samples obtained from people of the Han
Chinese origin. Three distinct intrinsic gene sets were
used, and the systemic microarray bias was accounted
for by carrying out mean-centring of genes or DWD.
We found that without adjustment, Sørlie 500 and Hu
306 signatures had a higher proportion of unclassified
cases, thereby highlighting the importance of eliminating
systemic bias and enhancing comparability across micro-
array studies. This was further supported by the high
kappa statistics between DWD and gene centring when
Sørlie 500 and Hu 306 intrinsic genes were used.
Among all the 3 intrinsic gene sets, PAM50 was less
sensitive to systemic adjustment but showed more nor-
mal breast-like samples (especially with DWD).
The number of breast cancer samples predicted as
normal breast-like subtype was largely influenced by
intrinsic genes used and adjustment method. Notably,
normal breast-like centroid in PAM50 was derived from
29 normal breast samples and should be treated as an
internal quality control rather than a breast cancer
intrinsic variation in Hu 306 and Sørlie 500 [6]. In this
sense, none of our samples should be predicted as nor-
mal breast-like subtype with PAM50. In our study, the
higher number of samples catogorised as the normal
breast-like subtype by PAM50 indicates possible normal
breast tissue contamination without laser capture micro-
dissection, or dubious predictive accuracy of PAM50
normal breast-like centroid derived from unrepresenta-
tive or limited number of normal breast samples.
Another possible explanation is that gene expression
values were obtained by microarray experiments rather
than reserve transcriptase polymerase chain reaction
(RT-PCR) used by the PAM50 signature, and this led to
some discrepancies in measurements.
We next compared the pairwise consistency between the
distinct intrinsic gene sets, under the same adjustment
manner. With gene centring, Hu 306 and PAM50 showed
the highest consistency (unweighted kappa: 0.85), or nearly
90% of the assayed samples were identified to be of the
same subtype. Hu 306 and PAM50 still showed the highest
agreement when adjusted by DWD, but only substantial
agreement (unweighted kappa: 0.67) was observed.
Because Sørlie 500 appeared the first in all 3 intrinsic sig-
natures, many of its clone ID identifiers had difficulties
mapping to the latest HUGO gene symbol and modern
microarray platform used in current study. Investigators of
the Stanford group also suggested the use of the most
Figure 1 Survival analysis of 44 Taiwanese breast cancers with Hu
306 intrinsic genes and mean-centring adjustment (a). Subgroup
analysis in ER-positive breast cancers (n=19), only luminal A and B
subtypes displayed due to the sparseness of other molecular
subtypes (b). Subgroup analysis in ER-negative breast cancers
(n=15), only basal-like and HER2-enriched subtypes displayed due to
the sparseness of other molecular subtypes (c). (abbreviations:
LumA: luminal A, LumB: luminal B, Her2, HER2-enriched, basal: basal-
like, Norm: normal breast-like subtype, Hu_cen: Hu 306 intrinsic
genes with mean-centring adjustment).
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recently updated PAM50 during molecular subtyping of
clinical samples [6,13]. Here, we discourage the use of
Sørlie 500 gene set for intrinsic subtyping. Regarding
adjustment method, gene-centring rather than DWD
might deliver more optimisitc results since fewer normal
breast-like samples were predicted, especially when
PAM50 intrinsic genes were used.
Some researchers might tend to use clinical phenotypes
as surrogates for breast cancer molecular subtypes such
that ER-positive tumours were analogous to luminal sub-
type, tumours with ER-negativity/HER2 over-expression
were analogous to HER2-enriched subtype, and tumours
with ER-negativity/HER2 negativity were analogous to
basal-like breast cancer [15,16]. Supplementary Table S3
(Additional file 3) showed the intrinsic subtype distrubu-
tions stratified by so-called “IHC subtype” in our study
and as expected, there was a substantial disagreement
between molecular subtype defined by intrinsic genes and
subtype determined by conventional IHC methods alone.
However, molecular subtypes were determined to be inde-
pendent of pathological markers and the investigtors of
PAM50 also argued that ER and HER2 status alone were
not accurate surrogates for ‘true’ intrinsic subtype status;
for instance, only 64% of cases with HER2 over-expression
were designated as HER2-enriched subtype in their study
[6]. The discrepancy between clinical HER2 phenotype
and molecular HER2-enriched subtype raised the serious
concern that whether these patients should be managed
according to IHC/FISH results or gene expression profiles
and this dispute remained inconclusive. In table 4 we sum-
marized pathological features of each molecular subtype
from samples presistantly predicted into identical subtype
by Hu 306 and PAM50 under both DWD and gene-cen-
tring adjustment (roughly 70% of all assayed samples). As
expected, luminal B showed more aggressive behaviors by
traditional prognostic features, all basal-like tumros were
ER negative, most HER2-enriched tumors showed IHC/
FISH HER2 overe-expression, whereas only two-thirds of
tumours with clinical ER-negativity/HER2 over-expression
were predicted as HER2-enriched subtype according to
the gene expression assays, and these findings were grossly
in concordance with our knowledge about each breast
cancer molecular subtype. For 44 Taiwanese breast can-
cers with survival data, we did find a trend toward good
prognosis for luminal A subtype and worse prognosis for
luminal B and HER2-enriched subtype, and a survival ben-
efit of basal-like over HER2-enriched subtype was also
observed, especially when subgroup analysis was per-
formed according by IHC ER status.
Our study had some limitations. First, we did not have
a sufficient sample size to determine the prognostic
value of each molecular sutbype upon breast cancer sur-
vival and multi-variate analysis incorporating clinical
and pathological factors was not possible. Second, a
prospective study design is needed to eliminate selection
bias and may be help to incorporate breast cancer mole-
cular subtypes into clinical decision makings.
Conclusions
In the current study we evaluted the prediction consis-
tency and clinical presentations of breast cancer molecu-
lar signatures trans-ethnically for Han Chinese
population. We found that with proper adjustments to
enhance comparability across microarray studies, the
predictive consistency between PAM50 and Hu 306 was
achieved for nearly 90% of our independent breast can-
cer samples, and disparities in the associated clinical
and pathological features were observed between distinct
molecular subtypes. A trend of prognostic disparity was
also observed from intrinsic subtypes among Taiwanese
breast cancers, and provides an opportunity for develop-
ing risk prediction models and dissecting the heteroge-
neity within ER positive and negative breast cancers
respectively. Further work to evaluate the relevance of
molecular subtypes and survival should be initiated
using more clinical samples with longer follow-up of
patients.
Additional material
Additional file 1: Supplementary materials and methods This file
included the mapping process of intrinsic genes to Affymetrix®®
probesets, and the source of Chinese breast cancer microarrays. Table S1
summarized intrinsic subtype distributions stratified by clinical
phenotypes.
Additional file 2: Supplementary Table S2 Supplementary Table S2
contained pairwise comparisons between 3 intrinsic gene lists for the
assignment of the samples.
Additional file 3: Supplementary Table S3 Table S3 showed the
distributions of molecular subtypes defined by intrinsic genes (Hu 306
and PAM50 with gene-centring and DWD) stratified by subtypes defined
by IHC results.
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